• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Comparison of New York Heart Association Class and Patient-Reported Outcomes for Heart Failure With Reduced Ejection Fraction.纽约心脏协会心功能分级与射血分数降低的心力衰竭患者报告结局的比较。
JAMA Cardiol. 2021 May 1;6(5):522-531. doi: 10.1001/jamacardio.2021.0372.
2
New York Heart Association Class and Kansas City Cardiomyopathy Questionnaire in Acute Heart Failure.纽约心脏协会心功能分级和堪萨斯城心肌病问卷在急性心力衰竭中的应用。
JAMA Netw Open. 2023 Oct 2;6(10):e2339458. doi: 10.1001/jamanetworkopen.2023.39458.
3
Patient-Reported Versus Physician-Assessed Health Status in Heart Failure With Reduced and Preserved Ejection Fraction From ASIAN-HF Registry.亚洲心力衰竭注册研究中射血分数降低和保留的心力衰竭患者自我报告与医生评估的健康状况
Circ Cardiovasc Qual Outcomes. 2023 Jan;16(1):e009134. doi: 10.1161/CIRCOUTCOMES.122.009134. Epub 2022 Dec 9.
4
Association of Serial Kansas City Cardiomyopathy Questionnaire Assessments With Death and Hospitalization in Patients With Heart Failure With Preserved and Reduced Ejection Fraction: A Secondary Analysis of 2 Randomized Clinical Trials.连续堪萨斯城心肌病问卷评估与射血分数保留和降低的心衰患者死亡和住院的相关性:两项随机临床试验的二次分析。
JAMA Cardiol. 2017 Dec 1;2(12):1315-1321. doi: 10.1001/jamacardio.2017.3983.
5
Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial.射血分数保留的心力衰竭患者的健康相关生活质量:PARAGON-HF 试验。
JACC Heart Fail. 2019 Oct;7(10):862-874. doi: 10.1016/j.jchf.2019.05.015. Epub 2019 Jul 10.
6
Characterization and natural history of patients with LMNA-related dilated cardiomyopathy in the phase 3 REALM-DCM trial.在3期REALM-DCM试验中,与LMNA相关的扩张型心肌病患者的特征及自然病史
ESC Heart Fail. 2024 Dec;11(6):4201-4208. doi: 10.1002/ehf2.14955. Epub 2024 Aug 15.
7
Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial.达格列净对射血分数降低的心力衰竭患者症状、功能和生活质量的影响:来自 DAPA-HF 试验的结果。
Circulation. 2020 Jan 14;141(2):90-99. doi: 10.1161/CIRCULATIONAHA.119.044138. Epub 2019 Nov 17.
8
Semaglutide and NYHA Functional Class in Obesity-Related Heart Failure With Preserved Ejection Fraction: The STEP-HFpEF Program.司美格鲁肽与肥胖相关性射血分数保留心力衰竭患者的 NYHA 心功能分级:STEP-HFpEF 研究计划。
J Am Coll Cardiol. 2024 Jul 16;84(3):247-257. doi: 10.1016/j.jacc.2024.04.038. Epub 2024 Jun 23.
9
Change of Health-Related Quality of Life Over Time and Its Association With Patient Outcomes in Patients With Heart Failure.随着时间的推移,健康相关生活质量的变化及其与心力衰竭患者预后的关系。
J Am Heart Assoc. 2020 Sep;9(17):e017278. doi: 10.1161/JAHA.120.017278. Epub 2020 Aug 19.
10
Health Status Variation Across Practices in Outpatients With Heart Failure: Insights From the CHAMP-HF (Change the Management of Patients With Heart Failure) Registry.心力衰竭门诊患者不同医疗实践中的健康状况差异:来自CHAMP-HF(改变心力衰竭患者管理)注册研究的见解
Circ Cardiovasc Qual Outcomes. 2018 Apr;11(4):e004668. doi: 10.1161/CIRCOUTCOMES.118.004668.

引用本文的文献

1
Reliability of a German version of the Kansas City Cardiomyopathy Questionnaire (KCCQ) administered via telephone.通过电话使用的德语版堪萨斯城心肌病问卷(KCCQ)的可靠性。
Sci Rep. 2025 Aug 4;15(1):28444. doi: 10.1038/s41598-025-14179-6.
2
Value of Early Diagnosis and Treatment of Amyloidosis: A Pilot Study of Synovial Biopsy During Carpal Tunnel Release.淀粉样变性早期诊断与治疗的价值:腕管松解术中滑膜活检的初步研究
J Hand Surg Glob Online. 2025 Jul 23;7(5):100779. doi: 10.1016/j.jhsg.2025.100779. eCollection 2025 Sep.
3
Factors Associated with Clinically Important Changes in Quality of Life of Heart Failure Patients: The QUALIFIER Prospective Cohort Study.与心力衰竭患者生活质量临床重要变化相关的因素:QUALIFIER前瞻性队列研究。
J Clin Med. 2025 Jul 17;14(14):5079. doi: 10.3390/jcm14145079.
4
Prevalence of Autonomic Dysfunction and Correlation with Markers of Disease Severity in Cardiac Amyloidosis.心脏淀粉样变性中自主神经功能障碍的患病率及其与疾病严重程度标志物的相关性
J Clin Med. 2025 Jul 2;14(13):4682. doi: 10.3390/jcm14134682.
5
Cardiovascular-kidney-metabolic overlaps, clinical outcomes, and quality of life in patients with acute heart failure.急性心力衰竭患者的心血管-肾脏-代谢重叠、临床结局及生活质量
J Nutr Health Aging. 2025 Aug;29(8):100613. doi: 10.1016/j.jnha.2025.100613. Epub 2025 Jun 23.
6
Safety and Efficacy of Tafamidis in Chinese Patients with Transthyretin Amyloid Cardiomyopathy.他法米地对中国转甲状腺素蛋白淀粉样心肌病患者的安全性和有效性
Cardiol Ther. 2025 May 23. doi: 10.1007/s40119-025-00408-6.
7
Burden of Treatment in Patients With Heart Failure.心力衰竭患者的治疗负担
J Am Heart Assoc. 2025 May 20;14(10):e039695. doi: 10.1161/JAHA.124.039695. Epub 2025 May 15.
8
Heart failure and obesity: Translational approaches and therapeutic perspectives. A scientific statement of the Heart Failure Association of the ESC.心力衰竭与肥胖:转化方法与治疗前景。欧洲心脏病学会心力衰竭协会的科学声明。
Eur J Heart Fail. 2025 Jul;27(7):1273-1293. doi: 10.1002/ejhf.3676. Epub 2025 May 6.
9
Systematic evaluation of patient-reported outcomes in clinical trials of digital health in cardiovascular diseases.心血管疾病数字健康临床试验中患者报告结局的系统评价。
NPJ Digit Med. 2025 May 2;8(1):238. doi: 10.1038/s41746-025-01637-8.
10
Heart Failure With Preserved Ejection Fraction Phenotype Is Associated With Early Symptom Onset in Aortic Stenosis and Residual Symptoms After Transcatheter Aortic Valve Implantation.射血分数保留的心力衰竭表型与主动脉瓣狭窄的早期症状发作及经导管主动脉瓣植入术后的残留症状相关。
J Am Heart Assoc. 2025 May 6;14(9):e038786. doi: 10.1161/JAHA.124.038786. Epub 2025 Apr 16.

纽约心脏协会心功能分级与射血分数降低的心力衰竭患者报告结局的比较。

Comparison of New York Heart Association Class and Patient-Reported Outcomes for Heart Failure With Reduced Ejection Fraction.

机构信息

Duke Clinical Research Institute, Durham, North Carolina.

Division of Cardiology, Duke University School of Medicine, Durham, North Carolina.

出版信息

JAMA Cardiol. 2021 May 1;6(5):522-531. doi: 10.1001/jamacardio.2021.0372.

DOI:10.1001/jamacardio.2021.0372
PMID:33760037
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7992023/
Abstract

IMPORTANCE

It is unclear how New York Heart Association (NYHA) functional class compares with patient-reported outcomes among patients with heart failure (HF) in contemporary US clinical practice.

OBJECTIVE

To characterize longitudinal changes and concordance between NYHA class and the Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ-OS), and their associations with clinical outcomes.

DESIGN, SETTING, AND PARTICIPANTS: This cohort study included 2872 US outpatients with chronic HF with reduced ejection fraction across 145 practices enrolled in the CHAMP-HF registry between December 2015 and October 2017. All patients had complete NYHA class and KCCQ-OS data at baseline and 12 months. Longitudinal changes and correlations between the 2 measure were examined. Multivariable models landmarked at 12 months evaluated associations between improvement in NYHA and KCCQ-OS from baseline to 12 months with clinical outcomes occurring from months 12 through 24. Statistical analyses were performed from March to August 2020.

EXPOSURE

Change in health status, as defined by 12-month change in NYHA class or KCCQ-OS.

MAIN OUTCOMES AND MEASURES

All-cause mortality, HF hospitalization, and mortality or HF hospitalization.

RESULTS

In total, 2872 patients were included in this analysis (median [interquartile range] age, 68 [59-75] years; 872 [30.4%] were women; and 2156 [75.1%] were of White race). At baseline, 312 patients (10.9%) were NYHA class I, 1710 patients (59.5%) were class II, 804 patients (28.0%) were class III, and 46 patients (1.6%) were class IV. For KCCQ-OS, 1131 patients (39.4%) scored 75 to 100 (best health status), 967 patients (33.7%) scored 50 to 74, 612 patients (21.3%) scored 25 to 49, and 162 patients (5.6%) scored 0 to 24 (worst health status). At 12 months, 1002 patients (34.9%) had a change in NYHA class (599 [20.9%] with improvement; 403 [14.0%] with worsening) and 2158 patients (75.1%) had a change of 5 or more points in KCCQ-OS (1388 [48.3%] with improvement; 770 [26.8%] with worsening). The most common trajectory for NYHA class was no change (1870 [65.1%]), and the most common trajectory for KCCQ-OS was an improvement of at least 10 points (1047 [36.5%]). After adjustment, improvement in NYHA class was not associated with subsequent clinical outcomes, whereas an improvement of 5 or more points in KCCQ-OS was independently associated with decreased mortality (hazard ratio, 0.59; 95% CI, 0.44-0.80; P < .001) and mortality or HF hospitalization (hazard ratio, 0.73; 95% CI, 0.59-0.89; P = .002).

CONCLUSIONS AND RELEVANCE

Findings of this cohort study suggest that, in contemporary US clinical practice, compared with NYHA class, KCCQ-OS is more sensitive to clinically meaningful changes in health status over time. Changes in KCCQ-OS may have more prognostic value than changes in NYHA class.

摘要

重要性

目前尚不清楚纽约心脏协会(NYHA)功能分级与心力衰竭(HF)患者的患者报告结局在当代美国临床实践中的关系。

目的

描述 NYHA 分级与堪萨斯城心肌病问卷整体综合评分(KCCQ-OS)之间的纵向变化和一致性,并评估其与临床结局的相关性。

设计、设置和参与者:本队列研究纳入了 2015 年 12 月至 2017 年 10 月期间在 CHAMP-HF 注册中心登记的 145 家美国实践中心的 2872 例慢性射血分数降低型心力衰竭的门诊患者。所有患者在基线和 12 个月时均具有完整的 NYHA 分级和 KCCQ-OS 数据。检查了这两种测量方法的纵向变化和相关性。在 12 个月的时间点进行多变量模型分析,评估从基线到 12 个月时 NYHA 分级和 KCCQ-OS 的改善与 12 至 24 个月的临床结局之间的相关性。统计分析于 2020 年 3 月至 8 月进行。

暴露

健康状况的变化,定义为 12 个月 NYHA 分级或 KCCQ-OS 的变化。

主要结局和测量指标

全因死亡率、HF 住院率以及死亡率或 HF 住院率。

结果

共有 2872 例患者纳入本分析(中位数[四分位数间距]年龄,68[59-75]岁;872 例[30.4%]为女性;2156 例[75.1%]为白种人)。基线时,312 例(10.9%)患者为 NYHA 分级 I,1710 例(59.5%)为 II 级,804 例(28.0%)为 III 级,46 例(1.6%)为 IV 级。对于 KCCQ-OS,1131 例(39.4%)评分在 75 到 100 分(最佳健康状况),967 例(33.7%)评分在 50 到 74 分,612 例(21.3%)评分在 25 到 49 分,162 例(5.6%)评分在 0 到 24 分(最差健康状况)。在 12 个月时,1002 例(34.9%)患者 NYHA 分级发生变化(599 例[20.9%]改善,403 例[14.0%]恶化),2158 例(75.1%)患者 KCCQ-OS 评分变化≥5 分(1388 例[48.3%]改善,770 例[26.8%]恶化)。NYHA 分级最常见的变化轨迹是无变化(1870 例[65.1%]),KCCQ-OS 最常见的变化轨迹是改善至少 10 分(1047 例[36.5%])。经过调整,NYHA 分级的改善与随后的临床结局无关,而 KCCQ-OS 评分的改善≥5 分与死亡率降低独立相关(风险比,0.59;95%置信区间,0.44-0.80;P<0.001)和死亡率或 HF 住院率降低(风险比,0.73;95%置信区间,0.59-0.89;P=0.002)。

结论和相关性

本队列研究的结果表明,在当代美国临床实践中,与 NYHA 分级相比,KCCQ-OS 对健康状况随时间的变化更为敏感。KCCQ-OS 的变化可能比 NYHA 分级的变化具有更高的预后价值。